Michelle Dipp's guest appearances

Michelle Dipp

How Hard Can It Be?

This is ZAGENO

Code Revue

Matt Walsh

Eric Paley

David Cancel

Patrick Sweeney

Dave Balter

Adam Morgan

Jules Pieri

Steve Kraus

Patrick Murck

Steve Kokinos

Jeff McCarthy

Sarah Downey

Stefania Mallett

Mike Troiano

Jim Crowley

OwlTail

A conversation about Life Science investment trends with Michelle Dipp, MD PhD, Co-Founder and Managing Partner at Biospring Partners.

A conversation about Life Science investment trends with Michelle Dipp, MD PhD, Co-Founder and Managing Partner at Biospring Partners.

Investor Perspective: Life Science Manufacturing & Supply Chain with Michelle Dipp, Biospring Partners

My guest the week is healthcare VC superstar  Michelle Dipp. Dr. Dipp is a co-founder and Partner of Longwood Fund, having co-founded Longwood portfolio companies Axial Biotherapeutics and OvaScience, both of which she now serves as Chairman of the Board. She previously served as the CEO of Alnara Pharmaceuticals (acquired by Eli Lilly), Verastem (NASDAQ: VSTM) and FlexPharma (NASDAQ: FLKS).  BOTH of whichMichelle Dipp is an overachiever in an industry of overachievers. As a young girl growing up in El Paso Texas, though, she dreamed of being a professional ballerina. She worked diligently at it for 8 years — studying under a Balanchine dancer from age 4 — before two attempts at New York auditions ended in heartbreak. Six years of strict Catholic school later, she failed again… this time to get into Harvard, which had become her “dream school” after coming to terms with her mother’s loving but pragmatic advice on ballet and on life. “Sometimes no matter how hard you work,” she said, “you’re just not going to be good enough. And you need to get over it.”Near as I can tell, Michelle Dipp was never not good enough for anything again. Her Oxford undergrad experience turned into 12 years of study abroad, culminating in a stint as a first class medical researcher. Her work, energy, and leadership skills garnered first the attention and then the high regard of both Big Pharma and Big Private Equity. Driven to the cutting edge of medical science, she used her power and influence to develop promising new platforms into a series of companies that would make any VC salivate. In her spare time she helped build the venture capital firm that would spawn them all — Longwood Fund — whose mission “to identify technologies and found companies that will advance new therapeutics that not only make a difference in the lives of patients worldwide, but also create significant value for investors.”Michelle Dipp wants it all. She wants what her mom had, which as a nurse in a Texas border town was to make a difference in the lives of real people across a broad spectrum of cultural and socioeconomic circumstances. And she wants what her dad had too, which is to build and lead businesses that make a difference in the community of which they are a part.That’s what Michelle Dipp wants. And there is simply no doubt she is good enough to get it.In our second segment this week Michelle and I talked about the differences, similarities, and inevitable convergence of the two great tribes of the Boston innovation ecosystem, Healthcare and Tech. Using the example of her latest project — Axial Biotheraputics — Michelle explains how new treatment “platforms” come about on the healthcare side, and the process by which enterprising entrepreneurs turn promising scientific breakthroughs into therapies that help people in the real world.Michelle is obviously a rock star, but also a delight to spend time with. I think you’re really going to enjoy getting to know her, in particular the person behind the pedigree.

My guest the week is healthcare VC superstar Michelle Dipp. Dr. Dipp is a co-founder and Partner of Longwood Fund, having co-founded Longwood portfolio companies Axial Biotherapeutics and OvaScience, both of which she now serves as Chairman of the Board. She previously served as the CEO of Alnara Pharmaceuticals (acquired by Eli Lilly), Verastem (NASDAQ: VSTM) and FlexPharma (NASDAQ: FLKS). BOTH of which Michelle Dipp is an overachiever in an industry of overachievers. As a young girl growing up in El Paso Texas, though, she dreamed of being a professional ballerina. She worked diligently at it for 8 years — studying under a Balanchine dancer from age 4 — before two attempts at New York auditions ended in heartbreak. Six years of strict Catholic school later, she failed again… this time to get into Harvard, which had become her “dream school” after coming to terms with her mother’s loving but pragmatic advice on ballet and on life. “Sometimes no matter how hard you work,” she said, “you’re just not going to be good enough. And you need to get over it.” Near as I can tell, Michelle Dipp was never not good enough for anything again. Her Oxford undergrad experience turned into 12 years of study abroad, culminating in a stint as a first class medical researcher. Her work, energy, and leadership skills garnered first the attention and then the high regard of both Big Pharma and Big Private Equity. Driven to the cutting edge of medical science, she used her power and influence to develop promising new platforms into a series of companies that would make any VC salivate. In her spare time she helped build the venture capital firm that would spawn them all — Longwood Fund — whose mission “to identify technologies and found companies that will advance new therapeutics that not only make a difference in the lives of patients worldwide, but also create significant value for investors.” Michelle Dipp wants it all. She wants what her mom had, which as a nurse in a Texas border town was to make a difference in the lives of real people across a broad spectrum of cultural and socioeconomic circumstances. And she wants what her dad had too, which is to build and lead businesses that make a difference in the community of which they are a part. That’s what Michelle Dipp wants. And there is simply no doubt she is good enough to get it. In our second segment this week Michelle and I talked about the differences, similarities, and inevitable convergence of the two great tribes of the Boston innovation ecosystem, Healthcare and Tech. Using the example of her latest project — Axial Biotheraputics — Michelle explains how new treatment “platforms” come about on the healthcare side, and the process by which enterprising entrepreneurs turn promising scientific breakthroughs into therapies that help people in the real world. Michelle is obviously a rock star, but also a delight to spend time with. I think you’re really going to enjoy getting to know her, in particular the person behind the pedigree.

HHCIB 026 Michelle Dipp & Making A Difference